Quantcast
Last updated on April 18, 2014 at 8:31 EDT

Latest Blood disorders Stories

2012-04-19 05:15:30

(Ivanhoe Newswire) -- According to a recent study, two related enzymes, phosphoinositide-3 kinase (PI3k) gamma and delta, have been found to have a role in the development of an aggressive childhood leukemia (T-cell acute lymphoblastic leukemia (T-ALL)) that is highly difficult to treat. The study sets the stage for clinical trials by revealing that a dual PI3K gamma/delta inhibitor can prolong survival in a mouse model of the disease and the dual inhibitor can prevent proliferation and...

2012-04-18 22:21:04

SEATTLE and SINGAPORE, April 19, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) and S*BIO Pte Ltd announced today that the companies have entered into an asset purchase agreement pursuant to which CTI would acquire world-wide rights to S*BIO's pacritinib, a highly selective JAK2 inhibitor. Pacritinib is an oral JAK2 (Janus Associated Kinase 2) selective inhibitor that has demonstrated encouraging clinical benefit in phase 1 and 2 clinical studies in patients with...

2012-04-17 02:27:47

MONTREAL, April 17, 2012 /PRNewswire/ -The CML Society of Canada commends the Ontario government for the recent decision to add Sprycel (dasatinib) and Tasigna (nilotinib) to the list of CML (chronic myelogenous leukemia) treatments reimbursed in first line, giving patients newly diagnosed with CML more treatment options earlier.  As patient advocates for equal access to all available therapies, the CML Society of Canada feels it is important that governments are aware that it is...

2012-04-16 22:25:08

Inhibiting 2 related enzymes significantly improves survival in mouse model of the disease Columbia University Medical Center (CUMC) scientists have demonstrated that two related enzymes – phosphoinositide-3 kinase (PI3K) gamma and delta – play a key role in the development of T-cell acute lymphoblastic leukemia (T-ALL), a highly aggressive childhood leukemia that is difficult to treat. The study also showed that a dual PI3K gamma/delta inhibitor can significantly prolong...

2012-04-16 10:24:04

KING OF PRUSSIA, Pa. and MONTREAL, April 16, 2012 /PRNewswire/ -- To mark World Hemophilia Day 2012, CSL Behring has again committed to making significant financial contributions and donations of clotting factor concentrate to the World Federation of Hemophilia (WFH) Global Alliance for Progress (GAP) program over the period of three years, beginning in 2012. The product donations will be made with medicine having a minimum shelf-life of one year. The goal of the WFH GAP program is to improve...

2012-04-16 10:23:58

MONTREAL, April 16, 2012 /PRNewswire/ -- An estimated one in 1,000 women and men has a bleeding disorder. However, 75 percent still receive very inadequate treatment or no treatment at all. What will it take to Close the Gap? To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/world-hemophilia-day----april-17-147623835.html On World Hemophilia Day 2012, the global bleeding disorders community will spread the message to "Close the...

2012-04-16 11:48:23

Use of new gene-sequencing technology rapidly identifies mutations that lead to drug resistance Through a groundbreaking new gene sequencing technology, researchers have demonstrated that the gene FLT3 is a valid therapeutic target in Acute Myeloid Leukemia, AML, one of the most common types of leukemia. The technique, developed by Pacific Biosciences, allows for the rapid and comprehensive detection of gene mutations in patients with AML. The findings, published online April 15 in...

2012-04-16 11:08:31

Gene mutations play critically important role in acute myeloid leukemia -- A promising development for new treatments The key to treating one of the most common types of human leukemia may lie within mutations in a gene called FLT3, according to new research led by physician-scientists at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. Published this week in the journal Nature, the work validates certain activating mutations in the...

2012-04-16 02:28:01

UNION CITY, Calif., April 16, 2012 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, has scheduled a conference call to discuss its financial results for the fourth quarter and fiscal year 2012, ended March 31, 2012. The call will be at 4:15 p.m. ET on Thursday, April 26, 2012. The Company will report financial results for the fourth quarter and fiscal year 2012 after the market closes on Thursday, April 26, 2012....

2012-04-16 02:27:59

SAN DIEGO, April 16, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company is a sponsor of and will be presenting at the Martin Center's 2012 Indiana Statewide Sickle Cell Disease Conference at the Indiana Landmarks Center in Indianapolis, Indiana on April 20, 2012. The conference seeks to bring awareness to the continued presence of sickle cell disease (SCD) and to inform the SCD community about current and proposed therapies for the...